BiotechTube

Cohort A: vilobelimab + Cohort A: placebo + Cohort B: paridiprubart + Cohort B: placebo + Cohort C: bevacizumab + Cohort C: placebo

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Respiratory Distress Syndrome (ARDS)

Conditions

Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome

Trial Timeline

Jun 10, 2025 → Sep 1, 2028

NCT ID
NCT06703073

About Cohort A: vilobelimab + Cohort A: placebo + Cohort B: paridiprubart + Cohort B: placebo + Cohort C: bevacizumab + Cohort C: placebo

Cohort A: vilobelimab + Cohort A: placebo + Cohort B: paridiprubart + Cohort B: placebo + Cohort C: bevacizumab + Cohort C: placebo is a phase 2 stage product being developed by InflaRx for Acute Respiratory Distress Syndrome (ARDS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06703073. Target conditions include Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome).

What happened to similar drugs?

20 of 20 similar drugs in Acute Respiratory Distress Syndrome (ARDS) were approved

Approved (20) Terminated (4) Active (0)
✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
✅PrasugrelDaiichi SankyoApproved
✅30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved
✅Sitafloxacin + Moxifloxacin HydrochlorideDaiichi SankyoApproved
✅micafungin + posaconazoleAstellas PharmaApproved
✅Selbex + SelbexEisaiApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06703073Phase 2Recruiting

Competing Products

20 competing products in Acute Respiratory Distress Syndrome (ARDS)

See all competitors
ProductCompanyStageHype Score
mRNA-1403ModernaPhase 2
0
mRNA-1403ModernaPhase 3
0
DFN-02Dr. Reddy's LaboratoriesPhase 3
37
DFN-15 (Celecoxib Oral Solution) 62.5 mg + DFN-15 (Celecoxib Oral Solution) 125 mg + DFN-15 (Celecoxib Oral Solution) 250 mg + PlaceboDr. Reddy's LaboratoriesPhase 2
32
AFM28AffimedPhase 1
11
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
TRV130TrevenaPhase 3
30
TRV130 + Morphine + PlaceboTrevenaPhase 2
25
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
42
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
39
SPT-07A injectionSinopharmPhase 3
36
PRGN-3006 T CellsPrecigenPhase 1
27
BisantreneRace OncologyPhase 2
29
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
15
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
25
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
ZN-d5Zentalis PharmaceuticalsPhase 1
19